secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001193125-22-145656
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO Q1 net loss $29.8M, cash runway into Q1 2024; cystinosis trial fully enrolled
--------------------------------------------------------------------------------

- Net loss $29.8M in Q1 2022, up from $26.9M in Q1 2021.
- R&D expenses $19.3M; G&A $10.2M including severance costs.
- Cash and equivalents $161.7M as of Mar 31, 2022; runway into Q1 2024.
- Cystinosis Phase 1/2 trial fully enrolled (6 patients); new data at ASGCT.
- Plan to start company-sponsored trials in 2023 for cystinosis, Gaucher type 3, Hunter, Pompe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312522145656/0001193125-22-145656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312522145656/d356485d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-145656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer